Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy Richard Wilson, Jane Fridlyand, Yibing Yan et al. · Nature · 2012
Cited by 1,133 works. doi:10.1038/nature11249
Authors
- Timothy Richard Wilson
- Jane Fridlyand
- Yibing Yan
- Elicia M. Penuel
- Luciana Burton
- Emily W. Chan
- Jing Peng
- Eva Lin
- Yulei Wang
- Jeff A. Sosman
- Antoni Ribas
- Li Jiang
- John G. Moffat
- Daniel P. Sutherlin
- Hartmut Koeppen
- Mark A. Merchant
- Richard M. Neve
- Jeff Settleman
References
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- Friends or foes — bipolar effects of the tumour stroma in cancer
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling